Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
Status:
Recruiting
Trial end date:
2023-02-13
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, open-label, multi-center clinical study evaluating the
effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have
initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic
treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI
in the hospital for at least 7 full days. There are no formal hypothesis tests planned for
this study. The number and percent of participants having clinical cure, failure, and
indeterminate at TOC visit in the cMITT analysis population will be summarized.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime